FGF23 and chronic kidney disease: We demonstrated that, after adjustment for cofounders, CKD patients with low serum α-Klotho levels (≤313 pg/mL) and high serum FGF-23 levels (≥168 pg/mL) are at high risk of adverse cardiovascular outcomes.